Anti-CXCR4/CD184 Antibody represents a highly specialized monoclonal antibody specifically engineered to target the human C-X-C chemokine receptor type 4 (CXCR4) with exceptional binding affinity. It effectively facilitates the measurable blockade of the CXCL12/CXCR4 signaling axis across various preclinical experimental models to evaluate the modulation of cellular chemotaxis, hematopoietic stem cell mobilization, and the inhibition of tumor metastasis during strictly monitored laboratory observation periods and functional cell migration assays.